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Abstract
Over the past decade, several large registries of patients with idiopathic
pulmonary fibrosis (IPF) have been established. These registries are
collecting a wealth of longitudinal data on thousands of patients
with this rare disease. The data collected in these registries will be
complementary to data collected in clinical trials because the patient
populations studied in registries have a broader spectrum of disease
severity and comorbidities and can be followed for a longer period of
time. Maintaining the quality and completeness of registry databases
presents administrative and resourcing challenges, but it is important
to ensuring the robustness of the analyses. Data from patient
registries have already helped improve understanding of the clinical
characteristics of patients with IPF, the impact that the disease has on
their quality of life and survival, and current practices in diagnosis and
management. In the future, analyses of biospecimens linked todetailed
patient profiles will provide the opportunity to identify biomarkers
linked to disease progression, facilitating the development of precision
medicine approaches for prognosis and therapy in patients with IPF.
Keywords: interstitial lung diseases; pulmonary fibrosis;
observational study; biomarkers
A registry can be defined as a longitudinal,
systematic collection of “real-world”
data describing the health status and
medical interventions in a defined
population of individuals. Patient
registries enable the collection of real-
world data on the clinical course of
diseases and their impact on patients
and healthcare services. Registries are
particularly useful in the case of rare
diseases, for which only a small number
of patients are seen at any individual
center (1). Idiopathic pulmonary fibrosis
(IPF) is a rare interstitial lung disease
(ILD), with an estimated U.S. incidence
of 3–10 per 100,000 person-years (2).
Before the creation of patient registries,
most data on the natural history of
IPF came from small, usually single-
center, observational studies and from
analyses of the placebo groups of clinical
trials of investigational therapies (3).
Although these studies provided valuable
data on the clinical course of IPF,
they were limited by their relatively
small size and short duration of follow-up
and the restricted patient populations
studied. The establishment of patient
registries has enabled the collection
of data from cohorts of patients with
IPF with a broader spectrum of disease
severity and comorbidities managed
in clinical practice, thereby providing
a better understanding of the real-
world behavior and impact of IPF.
In addition, many IPF registries
collect a range of biological samples,
with the aim of linking clinical
features or outcomes to disease
pathobiology. The vast number and
heterogeneity of patients, the large
number of outcome events, and the
prolonged duration of follow-up in
registries promise the possibility of
leveraging biobank data to develop and
validate individualized diagnostic and
therapeutic approaches (i.e., precision
medicine).
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Opportunities and Challenges
Presented by IPF Registries
The insights gleaned from patient registries
are complementary to those gained from
clinical trials. Although clinical trials
are designed to assess the effects of
interventions in carefully defined patient
populations, the populations studied in
registries are larger and more heterogeneous
(Table 1). Registry data provide a unique
opportunity to answer the question of
long-term effectiveness of antifibrotic
medications, including in patients with
greater disease severity than those studied
in clinical trials and patients with specific
comorbidities. In recent years, many IPF
registries have been initiated across the
world that will accumulate data on
several thousand patients (Table 2). In
aggregate, the number of patients
enrolled in these registries is a
tremendous advantage, providing the
power to discover new clinical or
biological variables and the capacity to
validate or refute findings derived from
smaller cohorts. These registries are
collecting similar categories of data, and
some have common data fields. However,
caution should be used in comparing data
collected in different registries, given the
differences in the patient populations
enrolled and the methodologies used to
collect and categorize data; even “the
same” parameter may not have been
assessed in the same way in different
registries. Although variability between
registries poses difficulties in comparison
of their results, the differences between
registries can theoretically also be
exploited to glean novel insights about
IPF.
The real-world nature of patient
registries poses challenges for data collection
and analysis. For registries in IPF, even the
application of diagnostic criteria is not
straightforward. IPF patient registries set up
before 2018 were largely designed to enroll
patients who met the diagnostic criteria
published in 2011 (4). However, some
registries rely on local diagnosis by site
investigators, whereas others have the
diagnosis confirmed at the enrolling center
or by central review. Substantial variability
may exist between enrolling centers
regarding the comprehensiveness of
testing for connective tissue diseases,
the assessment of exposures, and the
interpretation of high-resolution computed
tomographic scans. In some registries
(e.g., CARE-PF [Canadian Registry for
Pulmonary Fibrosis]), all the enrolling
centers are specialized referral centers,
whereas other registries (e.g., the Australian
Idiopathic Pulmonary Fibrosis Registry)
include a much broader range of
pulmonary practices. These differences
in methodology mean that the patient
populations enrolled in different
registries vary in the extent to which they
would meet the strictest application of
diagnostic guidelines. The publication
of new diagnostic guidelines for IPF in
September 2018 (5) will create additional
complications in analyzing data collected in
registries over time.
The timing of diagnosis is another
complicating factor. For many patients with
IPF, there is a prolonged period between
symptom onset and diagnosis due to delays
in presentation and referral and the time
needed to acquire diagnostic data (6–8).
Furthermore, the enrolling center for a
registry may not be the center at which the
patient first received their diagnosis of IPF.
This means that the patients enrolled in IPF
registries are at different points in the
course of the disease, and it is often not
clear when their IPF first developed. Some
registries split patients into those with
“incident” (diagnosed in past 6 mo) and
“prevalent” IPF (9), but this does not
entirely resolve the problem, because many
patients with newly diagnosed IPF will have
had the (undiagnosed) disease for some
time.
Registry data are maximally useful
when the data are complete, with stringent
quality control, but this poses administrative
and resourcing challenges (10), which may
vary across registries. Missing data may be
substantial for some variables. A number of
statistical techniques exist for handling
missing data (11, 12), but none is without
limitations. In particular, missing data
complicate the analysis and interpretation
of longitudinal analyses. Given that a
particularly salient benefit of registries
is the assessment of events over time
(e.g., hospitalizations, continuation of
antifibrotic therapy, change in health-related
Table 1. Key Differences between Clinical Trials and Patient Registries
Clinical Trials Registries
Diagnosis Narrowly defined based on diagnostic guidelines May not require strict adherence to diagnostic
guidelines; may allow for evolution of disease
definition if broad inclusion criteria are used and
adequate descriptive data are collected
Severity of disease Generally target middle ranges; several exclusions
related to comorbidities
All strata
Follow-up Usually more frequent and comprehensive than is
typical of clinical practice
Typically reflects clinical practice
Outcomes studied Focus on pulmonary function tests and health-related
quality of life
Course and impact of disease over long term,
including mortality
Generally too short to investigate mortality Detailed data on healthcare use and costs
Few data on healthcare use and costs
Duration Months to a few years May last several years
Data quality Few missing data; stringent quality control Substantial missing data; variable data quality
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Table 2. Ongoing Multicenter National/International Registries Including Patients with Idiopathic Pulmonary Fibrosis
Registry Name
(www.clinicaltrials.gov Identifier) Country/Countries Patient Population Size
IPF-PRO/ILD-PRO Registry
(NCT01915511)
United States Patients with IPF or other
progressive ILD that is newly
diagnosed or newly confirmed at
the enrolling center
1,000 patients with IPF (fully enrolled);
1,000 patients with progressive
non-IPF ILDs to be enrolled
PFF-PR (NCT02758808) United States ILDs, including IPF 1,461 patients enrolled as of August
2018; target is 2,000 patients,
z60% of whom have IPF (19)
Pulmonary Fibrosis Foundation
Contact Registry (NCT01935726)
United States Pulmonary fibrosis of any cause (and
caregivers of these patients)
Target enrollment is 50,000 patients
CARE-PF Canada ILDs, including IPF .3,000 patients enrolled, .600 of
whom have IPF
AIPFR Australia IPF 768 patients enrolled
Australasian ILD Registry Australia and New Zealand ILDs, including IPF 1,003 patients enrolled
EMPIRE Croatia, Czech Republic, Hungary,
Israel, Poland, Serbia, Slovakia,
and Turkey
IPF .2,048 patients enrolled (34)
eurIPFreg (NCT02951416) Austria, Czech Republic, France,
Germany, Hungary, Italy, Spain,
and United Kingdom (open to all
European countries)
ILDs, including IPF 525 patients with IPF enrolled as of
October 2016 (20); target enrollment




Germany Incident (diagnosed within 6 mo) and
prevalent IPF
Target is 1,000 patients with IPF
(almost fully enrolled)
EXCITING registry (NCT02645968) Germany ILDs, including IPF 601 patients enrolled, including 151
patients with IPF (57); enrollment is
complete
FinnishIPF registry Finland IPF .700 patients enrolled (58)
PROOF and PROOF-NEXT
(NCT03732859) registries
Belgium and Luxembourg IPF 277 patients enrolled in PROOF (21);
target enrollment in PROOF-NEXT
is 600 patients
Swedish IPF-Registry Sweden IPF .217 patients with IPF enrolled as of
May 2018 (59)
FIBRONET registry (NCT02803580) Italy IPF 210 patients enrolled (completed)
(www.clinicaltrials.gov)
INDULGE IPF (NCT03074149) Greece IPF Target enrollment is 300 patients (60)
REGIS Romania ILDs, including IPF .104 patients enrolled (61)
TURK-UIP (NCT02821039) Turkey ILDs with UIP on HRCT Target enrollment is 2,000 patients
(www.clinicaltrials.gov)
BTS United Kingdom IPF, sarcoidosis 2,000 patients with IPF and 400
patients with sarcoidosis enrolled
PORTRAY registry (NCT03666234) China Newly diagnosed IPF Target enrollment is 800 patients
ILD-India registry India ILDs, including IPF .1,084 patients enrolled (62)
JIPS registry (NCT03041623) Japan Newly diagnosed idiopathic ILDs,
including IPF
.498 patients enrolled, .249 of
whom have IPF (63); target
enrollment is 600 patients
Definition of abbreviations: AIPFR=Australian IPF Registry; BTS=British Thoracic Society; CARE-PF=Canadian Registry for Pulmonary Fibrosis;
EMPIRE=European MultiPartner IPF Registry; eurIPFreg=European IPF Registry and Biobank; EXCITING=Exploring Clinical and Epidemiological Characteristics of
Interstitial Lung Diseases; FIBRONET= IPF Italian observational study; HRCT=high-resolution computed tomography; ILD= interstitial lung disease; INDULGE
IPF= Investigating Idiopathic Pulmonary Fibrosis in Greece; INSIGHTS-IPF= Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis; IPF= idiopathic
pulmonary fibrosis; IPF-PRO/ILD-PRO= Idiopathic Pulmonary Fibrosis/Interstitial Lung Disease Prospective Outcomes; JIPS=Japanese Idiopathic Interstitial
Pneumonias; PFF-PR=Pulmonary Fibrosis Foundation Patient Registry; PORTRAY= Idiopathic Pulmonary Fibrosis Registry China Study; PROOF=Prospective
Observational Registry to Describe the Disease Course and Outcomes in Idiopathic Pulmonary Fibrosis; PROOF-NEXT=Prospective Observational Registry to
Describe the Disease Course and Outcomes in Idiopathic Pulmonary Fibrosis Patients in a Real-World Clinical Setting: New and Extended Belgium-Luxembourg;
REGIS=Romanian Registry for Interstitial Lung Diseases; TURK-UIP=Turkish Thoracic Society Usual Interstitial Pneumonia registry study; UIP=usual interstitial
pneumonia.
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quality of life [HRQoL]), biased loss of
follow-up is a major hurdle that must be
carefully considered in the design and
implementation of registries. The fact that
patients with worse disease are more likely
to drop out of a registry (due to death and
other reasons) means that data collected
over time may show better patient outcomes
than would have been observed if all patients
had been retained. However, it is also possible
that patients with milder or less progressive
disease may be less motivated to return to
tertiary centers, producing the opposite bias. If
resources permit, missing data can be
minimized using innovative approaches for
communicating with patients, such as using
call centers or telehealth technologies to follow
up directly with patients who have not
attended the enrolling center within a certain
time window. If permission has been obtained,
administrative data, such as from insurance
claims or health records, can potentially be
used to fill gaps in the registry database.
Key Insights from IPF
Registries to Date
Registries have provided a wealth of
information about the characteristics of
patients with IPF. In most registries, the
characteristics of patients at enrollment
appear similar to those of patients enrolled
in phase III trials such as the ASCEND
(Assessment of Pirfenidone to Confirm
Efficacy and Safety in Idiopathic Pulmonary
Fibrosis) (13) and INPULSIS (14) trials,
with patients being predominantly elderly,
male, and ex-smokers with significant lung
function impairment (Table 3) (15–21).
The INSIGHTS-IPF (Investigating Significant
Health Trends in Idiopathic Pulmonary
Fibrosis) registry in Germany appears to be an
exception in that the patients in this registry
had more severe gas exchange impairment at
baseline (mean DLCO, 35.5% predicted) than
patients in other registries or in most clinical
trials (9). Patients in IPF registries generally
have slightly worse scores on instruments
assessing symptoms and HRQoL than patients
in clinical trials (9, 22, 23). Data from several
registries suggest that HRQoL is worse in
patients who have more impaired lung
function, have worse dyspnea or cough, or are
using supplemental oxygen (22–25).
Data from patient registries have
helped to illuminate the prevalence of
comorbidities in patients with IPF. Among
the first 525 patients enrolled in the
eurIPFreg registry (European IPF Registry
and Biobank) (20) and the first 502 patients
enrolled in the German INSIGHTS-IPF
registry (9), arterial hypertension was present
in 32% and 54% of patients, respectively.
Among patients in the INSIGHTS-IPF,
eurIPFreg, and IPF-PRO (Idiopathic
Pulmonary Fibrosis Prospective Outcomes)
registries, pulmonary hypertension was
reported in 17%, 17%, and 8% and coronary
heart disease/coronary artery disease was
reported in 25%, 18%, and 29%, respectively
(9, 16, 20). Sleep disorders such as sleep apnea
were reported in approximately one-fourth of
patients in the eurIPFreg and U.S. registries
(16, 19, 20). Gastroesophageal reflux disease
was reported in 28% and 29.5% of patients in
the eurIPFreg and INSIGHTS-IPF registries,
respectively (9, 20), and in 47%, 55%, and 62%
of patients in the PROOF (Prospective
Observational Registry to Describe the Disease
Course and Outcomes of Idiopathic
Pulmonary Fibrosis Patients in a Real-world
Clinical Setting), IPF-PRO, and Pulmonary
Fibrosis Foundation registries, respectively (16,
19, 21). Registry data will provide the
opportunity to investigate the impact of
specific comorbidities on morbidity, mortality,
HRQoL, and healthcare resource use.
Registries are perhaps the most important
source of data on current practices in the
diagnosis of IPF and ultimately will allow
evaluation of temporal trends in diagnostic
procedures. For example, surgical lung biopsies
have been performed in 13–35% of patients
enrolled in registries (9, 16, 19–21, 26). In
eurIPFreg, 20–30% of patients diagnosed with
IPF in 2010–2011 had open or thoracoscopic
lung biopsy, but these numbers declined in the
following years (20). Rates of bronchoscopy
and analysis of BAL fluid (BALF) vary widely
across registries, with analysis of BALF
conducted in 85% of patients in eurIPFreg (20)
and 62% of patients in INSIGHTS-IPF (9),
whereas bronchoscopy was performed in only
about 20% of patients in the Australian IPF
registry (15) and an even smaller proportion of
patients in the IPF-PRO Registry (26). Data
from the INSIGHTS-IPF, Pulmonary Fibrosis
Foundation, and IPF-PRO registries suggest
that multidisciplinary discussion (MDD) was
performed at the enrolling center in 22%, 40%,
and 42% of patients, respectively (9, 19, 26). It
is unclear to what extent diagnoses made
without MDD reflect clinicians’ belief that
MDD was not required to make a diagnosis of
IPF in a particular patient, rather than a lack of
access to a multidisciplinary team. In
the Australian IPF Registry, a central
multidisciplinary review was implemented to
overcome the paucity of local access to MDD.
It should also be noted that there is no
standard definition of MDD in the diagnosis
of IPF, and different sites/registries may have
interpreted “MDD” in very different ways.
Interestingly, recent data from the Australian
IPF Registry showed that patients who had
received a clinical diagnosis of IPF but were
judged not to meet 2011 international
diagnostic guidelines in a central
multidisciplinary review exhibited disease
behavior and mortality similar to those of
patients who met those diagnostic guidelines
(27). These findings highlight an important
function of patient registries: their ability to
confirm or challenge the validity of diagnostic
categorizations.
Registry data support the findings of
patient surveys which indicate that patients
often experience a delay in diagnosis.
Among the first 525 patients participating
in eurIPFreg, the average time between
onset of symptoms and diagnosis of IPF was
21.8 months (20). Other registries have
reported similar findings (9, 17). However,
determination of the time from onset of
symptoms to diagnosis of IPF in patient
registries is confounded by the fact that most
patients with IPF are diagnosed and managed
by local physicians; thus, the date that a
patient is referred to an enrolling center is not
the date of diagnosis, and the time taken for a
patient to be referred to an enrolling center
may be highly variable between sites.
One of the greatest benefits provided by
patient registries is the opportunity to study
the clinical course of diseases in the real
world. Data from IPF registries demonstrate
the progressive nature of IPF (17, 22,
28–30). Among 514 patients participating
in the EMPIRE registry (European
MultiPartner IPF Registry), 23.5% of
patients had a decline in FVC greater than
or equal to 10% predicted over the course of
12 months (17). In the Australian IPF
registry, over a median follow-up period
of about 2 years, FVC declined by
approximately 5% predicted per year (28).
Registry data also illustrate the very high
mortality associated with IPF. In the
INSIGHTS-IPF registry, 36.5% of patients
died in the first 2 years after enrollment
(29). The factors shown to be associated
with higher mortality in patients with IPF
in registry studies are largely consistent
with the findings of clinical trials and
smaller observational studies. Advanced age
and worse lung function (FVC and DLCO)
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have consistently been shown to be
predictors of mortality in IPF registries
(15, 17, 30). A recent analysis of data from
662 patients in the IPF-PRO Registry
demonstrated that use of supplemental
oxygen at rest was the strongest predictor of
mortality over a follow-up period of 30
months (30). In addition, analyses of data
from the IPF-PRO Registry and the
Australian IPF Registry (15) suggest that
worse scores on patient-reported outcomes
such as the St. George’s Respiratory
Questionnaire provide important
prognostic information beyond that
provided by demographic/physiological
factors.
IPF is known to be associated with high
use of healthcare resources and high costs,
particularly related to hospitalization (31,
32). This is supported by real-world data
from patient registries. In the INSIGHTS-
IPF registry, 38.8% of patients were
hospitalized at least once over a 2-year
period (28). In the IPF-PRO Registry, the
probability of hospitalization was 30.2%
over 12 months and was higher among
those with more severe lung function
impairment at enrollment (33). Mean
length of hospital stay in patients who
did not undergo lung transplant was
5 days (33).
Finally, IPF registries are starting to
provide data on the use of approved drug
therapies (nintedanib and pirfenidone).
Data from eurIPFreg illustrate that
approved antifibrotic therapies now
dominate the drugs used to treat IPF (20).
However, many patients with IPF still do
not receive an antifibrotic therapy. Recent
data from IPF registries in the United States
showed that 55–62% of patients with IPF
were receiving nintedanib or pirfenidone at
enrollment (16, 19). Although registries
have already provided some data suggesting
that the use of antifibrotic therapies may
extend life expectancy in patients with IPF
(15, 20, 34, 35), the magnitude and
durability of this benefit will become clearer
with the availability of longer-term data.
Biobanking
“Biobanking” refers to the collection,
processing, storage, and distribution of
biological specimens, such as tissue; serum;
plasma; whole blood; or other bodily fluids,
such as urine, sputum, or BALF. Although
biobanks may be created with specific
hypotheses in mind, many biobanks also
have the forward-thinking purpose to store
samples that might be used in the future to
address new hypotheses (36). However,
given the substantial cost of biobanking,
registries may decide to prioritize certain
types of samples. The evolution of biobanks
into large interconnected operations
has led to the development of best
practice guidelines covering their
complex administrative and operational
requirements (37–39). In addition to
planning related to governance, funding,
equipment, storage, and personnel, there
are many ethical and legal aspects to
consider, including policies for obtaining
and withdrawing consent, patient
confidentiality, return of incidental
findings, and the transfer of biospecimens
and data (37, 38, 40). The success of a
biobank depends on adequate sample
quality. A stringent quality management
system is critical to minimizing the effects
of preanalytic and analytic factors and
ensuring uniformity in specimen handling
(36–38, 41).
A myriad of techniques are





immunofluorescence staining, and analysis
of neoepitopes (42–45). Modern high-
throughput techniques can generate a
massive quantity of data. Systems biology,
which uses predictive computational
modeling to analyze complex biological
systems and their interactions, is a field
that has evolved largely from the
development of these technologies (46).
Advances in artificial intelligence
applications have enabled very large and
complex datasets to be analyzed through
machine learning. These methods can be
used to identify distinct phenotype profiles
in a dataset, either by classifying samples
on the basis of a known set of features or
by unveiling groupings by clustering
samples on the basis of their similarities
(47–49). Coupled with clinical data, this
biological information is likely to radically
alter the diagnosis and management of IPF
in future years (50).
Biobanks have particular value
when the biological samples are
matched to patients who have been
well characterized with respect to their
characteristics and outcomes (51, 52). In
the case of IPF, these characteristics
include demographics, diagnosis-related
data (e.g., serologies, radiographic
patterns, pathologic patterns), measures
of disease severity (e.g., pulmonary
function tests, patient-reported outcomes),
treatments, and comorbidities (53).
Longitudinal data can be particularly
useful because they enable changes
in biomarkers to be linked to changes
in health status. Biobanks are already
beginning to generate data, including
on blood biomarkers as predictors of
disease severity and disease progression
(54, 55). Importantly, the existence
of multiple biobanks provides the
opportunity to validate and compare
findings in different patient populations
to improve the application of precision
medicine approaches for prognosis and
therapy.
Needs and Future Directions
in IPF Registries
Registries will help fill the gaps in the
data collected in clinical trials because
they cover a broader patient population,
can collect information over patients’
lifetimes, and provide insights into the
delivery of care in the real world. Future
registry efforts should consider less
conventional/more broadly defined disease
definitions, recruitment in understudied
populations, novel phenotyping using
biomarkers, and creative analytic
methodologies, perhaps focused on
specific goals or hypotheses, rather than
reprising the ballooning number of current
efforts. Such innovative registries are likely
to provide new observations that propel
the field forward. It is hoped that current
registries will provide insights into
particular endotypes and phenotypes of
patents with IPF (perhaps based on
physiology, imaging, serum biomarkers, or
rates/patterns of progression) that are
relevant to prognosis and treatment.
Registries will also help illuminate the
impact of therapies on patient outcomes,
including life expectancy and healthcare
use, in the real world. These findings
may align with the Food and Drug
Administration’s Real World Evidence
initiative, which aims to incorporate real-
world data into decisions regarding drug
labeling and indications and comparative
effectiveness or safety analyses (56).
CONCISE CLINICAL REVIEW
Concise Clinical Review 165
Several registries are collecting data on
other ILDs as well as IPF; these will help
improve understanding of the natural
history and outcomes of these ILDs, which
have not been studied as extensively as IPF
and for which there are no approved
therapies or established treatment
algorithms. Enrolling broader populations
will allow close examination of the
usefulness of transitory diagnostic
constructs and allow analyses of biological
questions that may cross over various
ILDs. Sharing data across registries will
increase the power to look at particularly
rare diseases, genotypes, phenotypes, and
events. Collaboration, transparency, and
effective application of technologies will
be critical to maximizing the value of
registries to researchers and ultimately to
patients.
Conclusions
Patient registries provide data that are
complementary to those provided by clinical
trials and administrative databases. The
heterogeneity of the patients in registries, as
compared with clinical trials, should be
regarded as one of registries’ strengths,
although the different patient populations
enrolled and methodologies used across
registries complicates comparison of their
findings. Data from patient registries have
already improved knowledge of the clinical
course and impact of IPF and of diagnostic
and treatment practices. The biobanks
associated with registries will be a valuable
resource to examine questions related to
pathogenetic mechanisms and prognostic
biomarkers and to facilitate the introduction
of personalized management strategies
for IPF. n
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